Pluripotent stem cell replacement approaches to treat type 1 diabetes

Research output: Contribution to journalArticlepeer-review

Abstract

Stem cells represent a potential candidate for β cell replacement in type 1 diabetes. Pluripotent stem cells are able to differentiate in vitro into functional insulin producing cells, that can restore normoglycemia in diabetic mice. Clinical trials with embryonic stem cell-derived pancreatic progenitors are ongoing. Besides, induced pluripotent stem cells offer the chance of personalized cell therapy. So far, transition to the clinic still needs to face critical issues, such as immunogenicity and safety of stem cell derived β cells. To this purpose, new strategies for immunoprotection, including micro and macro-encapsulation, but also gene editing approaches, are being explored. © 2018 Elsevier Ltd
Original languageEnglish
Pages (from-to)20-26
Number of pages7
JournalCurrent Opinion in Pharmacology
Volume43
DOIs
Publication statusPublished - 2018

Fingerprint Dive into the research topics of 'Pluripotent stem cell replacement approaches to treat type 1 diabetes'. Together they form a unique fingerprint.

Cite this